{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:50:31Z","timestamp":1791499831714,"version":"4.3.4"},"reference-count":0,"publisher":"Association of Basic Medical Sciences of FBIH","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomol Biomed"],"abstract":"<jats:p>Thyroid eye disease (TED) is an autoimmune orbital disorder in which interleukin-6 (IL-6) may reflect inflammatory activity. We evaluated tear IL-6 concentrations across disease activity groups, their association with the Clinical Activity Score (CAS), and paired tear\u2013serum differences. This prospective cross-sectional study included 42 adults: 15 with active TED (CAS \u22653), 14 with inactive TED (CAS 0\u20132), and 13 healthy controls. IL-6 was measured in diluted tear samples collected by micro-volume wash and paired serum using cytometric bead array with flow cytometry. Analyses comprised one-way analysis of variance, paired Student t-tests, and Pearson correlation. Mean tear IL-6 concentrations were 22.33, 8.49, and 3.82 pg\/mL in active TED, inactive TED, and controls, respectively, with a significant overall difference across groups (p\u00a0= 0.002). Tear IL-6 concentrations exceeded serum concentrations in active and inactive TED (p\u00a0= 0.001 and p\u00a0= 0.005, respectively), with no significant difference in controls (p\u00a0= 0.309). In active TED, tear IL-6 correlated positively with CAS (r = 0.55; 95% confidence interval, 0.05\u20130.83; p\u00a0= 0.032). These exploratory findings support further investigation of tear IL-6 as a correlate of clinical activity. Unmeasured ocular-surface status, unquantified tear dilution, and extrapolation below the assay\u2019s lowest calibrator limit interpretation; larger longitudinal studies incorporating objective ocular-surface assessment and assays validated for tear fluid are needed before clinical application.<\/jats:p>","DOI":"10.17305\/bb.2026.14860","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:07:40Z","timestamp":1791443260000},"source":"Crossref","is-referenced-by-count":0,"title":["Tear interleukin-6 and clinical activity in thyroid eye disease"],"prefix":"10.17305","author":[{"given":"Nayeli","family":"Alcaraz-Lares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7458-6149","authenticated-orcid":false,"given":"Daniel B.","family":"Mejia-Llanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Nava-Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6922","published-online":{"date-parts":[[2026,10,8]]},"container-title":["Biomolecules and Biomedicine"],"original-title":[],"link":[{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14860\/4349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/download\/14860\/4349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:00:41Z","timestamp":1791496841000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjbms.org\/ojs\/index.php\/bjbms\/article\/view\/14860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.17305\/bb.2026.14860","relation":{},"ISSN":["2831-090X","2831-0896"],"issn-type":[{"value":"2831-090X","type":"electronic"},{"value":"2831-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}